| Shen, Feng |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
NCT05913336: A Study of Remimazolam Tosilate for Prolonged Sedation in the ICU |
|
|
| Recruiting | 1/2 | 20 | RoW | Remimazolam Tosilate | Jiangsu HengRui Medicine Co., Ltd. | Sedation in the ICU | 11/23 | 11/23 | | |
| Recruiting | 1/2 | 103 | RoW | TQB2102 for injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Biliary Tract Cancer | 05/25 | 12/25 | | |
NCT05292443: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer |
|
|
| Withdrawn | N/A | 300 | RoW | Observation | Geneplus-Beijing Co. Ltd., Eastern Hepatobiliary Surgery Hospital | Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma | 03/23 | 03/23 | | |
| Chen, Wei |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
NCT05721404: Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis |
|
|
| Recruiting | 4 | 194 | RoW | Icodextrin Peritoneal Dialysis Solution, Hypertonic Dextrose solution | First Affiliated Hospital, Sun Yat-Sen University, Baxter Healthcare Corporation | Peritoneal Dialysis | 04/25 | 12/25 | | |
NCT06720233: Efficacy and Safety Study of SAL-0951 in the Treatment of Renal Anemia in Patients Receiving Peritoneal Dialysis |
|
|
| Completed | 3 | 37 | RoW | SAL-0951 tablets, SAL-0951 group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 10/24 | 10/24 | | |
NCT05629390: Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study |
|
|
| Completed | 3 | 163 | RoW | Lotilaner, TP-03, S-Misoxam, Vehicle Control | LianBio LLC | Blepharitis | 09/23 | 04/24 | | |
NCT06720025: Study of SAL-0951 Compared to Recombinant Human Erythropoietin in Anemic Patients Receiving Maintenance Hemodialysis |
|
|
| Completed | 3 | 100 | RoW | SAL-0951 tablets, SAL-0951 group, rHuEPO injection, rHuEPO group | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Anemia | 06/24 | 06/24 | | |
| Recruiting | 3 | 450 | Europe, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Perennial Allergic Rhinitis (PAR) | 10/25 | 02/27 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease |
|
|
| Recruiting | 3 | 400 | RoW | SJP-0132, Placebo | Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd. | Dry Eye | 07/25 | 08/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2/3 | 230 | Canada, US | MN-166, ibudilast, placebo | MediciNova | Amyotrophic Lateral Sclerosis | 12/25 | 12/26 | | |
NCT06470191: A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy. |
|
|
| Recruiting | 2/3 | 216 | RoW | B007, Cyclosporin Capsules | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Primary Membranous Nephropathy | 12/26 | 12/26 | | |
NCT05811442: Study of 50561 in Patients With Mild or Moderate Alzheimer's Disease |
|
|
| Recruiting | 2a | 60 | RoW | 50561 high dose, 50561 low dose, Placebo | Beijing Joekai Biotechnology LLC | Alzheimer's Disease | 05/24 | 06/24 | | |
NCT06435182: Study of OT202 in Treating Moderate to Severe Dry Eye |
|
|
| Completed | 2 | 213 | RoW | OT202 conc 0.5%, Investigational product, OT202 conc 0.1%, Placebo | Ocumension Therapeutics (Shanghai) Co., Ltd | Dry Eye | 01/24 | 01/24 | | |
NCT05810961: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) |
|
|
| Terminated | 2 | 8 | RoW | efgartigimod IV, placebo | argenx, Zai Lab Pty. Ltd. | Membranous Nephropathy | 08/24 | 08/24 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 07/25 | 09/25 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT06474416: A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis |
|
|
| Recruiting | 1 | 16 | RoW | BD111 Injection (Investigative New Drug), BD111 Lentivirus-like particles, HSV-1-erasing lentiviral particles, HELP, Triple-drugs therapy of HSV-1 stromal keratitis, Ganciclovir Ophthalmic Gel, Valacyclovir Hydrochloride Tablets, Prednisolone Acetate Ophthalmic Suspension | Shanghai BDgene Co., Ltd. | Herpes Simplex Virus Type I Stromal Keratitis | 09/25 | 09/25 | | |
NCT05633459: A Study Evaluating the Safety and Tolerability of QRL-201 in ALS |
|
|
| Recruiting | 1 | 64 | Europe, Canada | Multiple ascending doses of QRL-201, Multiple ascending doses of Placebo, QRL-201, Placebo | QurAlis Corporation | Amyotrophic Lateral Sclerosis | 08/26 | 08/26 | | |
NCT05570435: Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response |
|
|
| Completed | N/A | 31 | RoW | Blood collection | Société des Produits Nestlé (SPN), Peking Union Medical College Hospital | Healthy, PreDiabetes, Adult, Asian | 03/23 | 03/23 | | |
NCT05859165: To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes) |
|
|
| Recruiting | N/A | 250 | RoW | Nutren Diabetes, Fresubin Diabetes | Société des Produits Nestlé (SPN), Nestle Health Science | Diabetes Mellitus | 12/24 | 06/25 | | |
| Wang, Jian |
NCT04275323: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
|
|
| Completed | 3 | 302 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 06/24 | 06/24 | | |
| Completed | 3 | 242 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 12/23 | 12/23 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
NCT03716011: A Postmarket Clinical Trial for EXCROSSAL Stent in CAD Patients With 3-month DAPT or 12-month DAPT |
|
|
| Not yet recruiting | N/A | 2700 | RoW | EXCROSSAL | JW Medical Systems Ltd | Coronary Artery Disease | 12/21 | 12/25 | | |
NCT06239454: Interleaving Stimulation Improves Dyskinesia in Parkinson's Disease |
|
|
| Recruiting | N/A | 50 | RoW | interleaving stimulation, empirical stimulation | Huashan Hospital, Medtronic | Parkinson's Disease | 12/24 | 02/25 | | |
| Completed | N/A | 210 | RoW | OrbusNeich Scoreflex TRIO, OrbusNeich Scoreflex NC | OrbusNeich, CCRC Medtech (Shanghai) Co., Ltd. | Coronary Arteriosclerosis | 04/24 | 05/24 | | |
| Active, not recruiting | N/A | 51 | RoW | MitraClip procedure | Abbott Medical Devices | Mitral Regurgitation | 05/24 | 05/25 | | |
| Recruiting | N/A | 1017 | US, RoW | Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems | Medtronic Spinal and Biologics | Degenerative Disease of the Lumbosacral Spine | 04/26 | 04/28 | | |
| Wang, Ji Yao |
NCT03363763: Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex |
|
|
| Terminated | 2 | 24 | US, RoW | Sirolimus 0.2%, Rapamune, rapamycin, mTOR inhibitor, Sirolimus 0.4%, Placebo ointment, Placebo | Aucta Pharmaceuticals, Inc | Angiofibroma of Face, Tuberous Sclerosis | 03/23 | 03/23 | | |
| Cai, Xiujun |
NCT05862337: Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. |
|
|
| Recruiting | 3 | 480 | RoW | Anlotinib hydrochloride capsules, Penpulimab injection, Anlotinib hydrochloride capsules -matching placebo, Penpulimab injection -matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Hepatocellular Carcinoma | 08/24 | 12/26 | | |
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel |
|
|
| Completed | 3 | 571 | Europe, Canada, US, RoW | NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel | NovoCure Ltd. | Pancreas Adenocarcinoma | 10/24 | 10/24 | | |
NCT06560827: CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection |
|
|
| Recruiting | 1 | 30 | RoW | CT011 CAR-GPC3 T Cells Injection | CARsgen Therapeutics Co., Ltd., Shanghai Zhongshan Hospital | HCC | 12/26 | 06/27 | | |
NCT06019702: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen Alone in Subjects With Advanced Digestive System Neoplasms |
|
|
| Recruiting | 1 | 20 | RoW | iNeo-Vac-R01 | Sir Run Run Shaw Hospital, Hangzhou Neoantigen Therapeutics Co., Ltd. | Digestive System Neoplasms | 08/27 | 12/27 | | |
NCT06026800: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms |
|
|
| Recruiting | 1 | 20 | RoW | iNeo-Vac-R01 | Sir Run Run Shaw Hospital, Hangzhou Neoantigen Therapeutics Co., Ltd. | Digestive System Neoplasms | 08/27 | 12/27 | | |
NCT06026774: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms |
|
|
| Recruiting | 1 | 20 | RoW | iNeo-Vac-R01 in combination with standard adjuvant therapy | Sir Run Run Shaw Hospital, Hangzhou Neoantigen Therapeutics Co., Ltd. | Digestive System Neoplasms | 08/27 | 12/27 | | |
| Qin, Lunxiu |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
| Zhang, Yong |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
NCT05719688: Evaluate the Safety and Efficacy of Thrombectomy System in the Intravascular Treatment of Acute Ischemic Stroke |
|
|
| Recruiting | N/A | 200 | RoW | Mechanical thrombectomy | Suzhou Hengruihongyuan Medical Technology Co. LTD | Acute Ischemic Stroke | 12/23 | 12/24 | | |
NCT06365697: Evaluation of the Ton-bridge Carotid Stent for Carotid Artery Stenosis |
|
|
| Recruiting | N/A | 188 | RoW | Ton-bridge carotid stent, WALLSTENT carotid stent | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Carotid Artery Stenosis | 11/24 | 10/25 | | |
| Liu, Houbao |
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients. |
|
|
| Recruiting | 2 | 60 | RoW | SPH5030 | Shanghai Pharmaceuticals Holding Co., Ltd | Biliary Tract or Colorectal Cancer With Her2-positive/Mutated | 12/26 | 12/26 | | |
| Chen, Yajin |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Active, not recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 12/26 | 12/26 | | |
NCT05564338: Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma |
|
|
| Withdrawn | 3 | 684 | NA | Sitravatinib, Tislelizumab, sitravatinib-matching placebo, tislelizumab-matching placebo | BeiGene | Hepatocellular Carcinoma | 04/27 | 04/28 | | |
NCT04329429: A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 57 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection | RemeGen Co., Ltd. | Biliary Tract Cancer | 11/23 | 06/24 | | |
| Jin, Gang |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
AK104-217, NCT05859750: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 78 | RoW | AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin | Akeso | Pancreatic Cancer | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1 | 30 | RoW | Personalized neoantigen vaccine | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Pancreatic Tumor | 11/23 | 12/23 | | |
| Zheng, Minhua |
| No trials found |
| Mao, Zhaihai |
| No trials found |
| Deng, Guilong |
| No trials found |
| Zhou, Guangwen |
| No trials found |
| Zhou, Zunqiang |
| No trials found |
| Shi, Baomin |
| No trials found |
| Zhou, Donglei |
| No trials found |
| Shao, Chenghao |
| No trials found |
| Xu, Yunyao |
| No trials found |
| Liang, Xiao |
| No trials found |
| Sun, Xitai |
| No trials found |
| Shan, Xiaodong |
| No trials found |
